StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
ChemoCentryx (CCXI) sinks 45% as trading resumes following mixed FDA AdCom
May 7, 2021 7:15 AM
ChemoCentryx (NASDAQ: CCXI) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Momentum Movers
Trader Talk
Trading Halts
Next Articles
ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms
May 7, 2021 9:36 AM
Raymond James Downgrades ChemoCentryx (CCXI) to Outperform
May 7, 2021 7:38 AM
SVB Leerink Downgrades ChemoCentryx (CCXI) to Market Perform
May 7, 2021 7:01 AM
ChemoCentryx (CCXI) Reports Mixed FDA AdCom Vote For Avacopan
May 7, 2021 6:48 AM
UPDATE: Stifel Downgrades ChemoCentryx (CCXI) to Hold
May 7, 2021 4:01 AM
UPDATE: JPMorgan Downgrades ChemoCentryx (CCXI) to Underweight
May 7, 2021 4:01 AM
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
May 6, 2021 11:37 PM
